

IDS/#3
2/16/02
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

Re Application of:
Zheng Wu
Shuyuan Zhang

Serial No.: 09/941,296


Filed: August 28, 2001

For: FORMULATION OF ADENOVIRUS FOR
GENE THERAPY

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: INRP:067USD1/SLH

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date below:	
December 11, 2001	
Date	Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10107662/SLH.

This application is a divisional application of Serial No. 09/441,410, filed November 16, 1999 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/441,410.

Applicants respectfully request that the listed documents be made of record in the present case.


Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: December 11, 2001



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

STEVEN L. HIGHLANDER
PARTNER

INTERNET ADDRESS:
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

164S
IDS/#3
2/16/02

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG


RECEIVED

FEB 04 2002

TECH CENTER 1600/2900 FILE: INRP:067USD1

December 11, 2001

**COPY OF PAPERS
ORIGINALLY FILED**

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
December 11, 2001	
Date	
	Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

RE: SN 09/941,296 "FORMULATION OF ADENOVIRUS FOR GENE THERAPY" –
Zheng Wu and Shuyuan Zhang


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement and Form PTO-1449.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10107662/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/cmb
Encl: as noted

RECEIVED

FEB 04 2002

Form PTO-1449 (modified)

Atty. Docket No.

INRP:067USD1/SLH

Serial No.

09/941,296

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Zheng Wu

Shuyuan Zhang

Filing Date:

August 28, 2001

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

TECH CENTER 1600/2900

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,797,368	1/10/89	Carter <i>et al.</i>	435	320	3/15/85
	A2	5,139,941	8/18/92	Muzycka <i>et al.</i>	435	172.3	10/25/91
	A3	5,552,309	9/3/96	March	435	172.3	9/30/94
	A4	5,789,244	8/4/98	Heidrum <i>et al.</i>	435	320.1	1/8/96

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	1279843	11/10/89	Japan			ABSTRACT
	B2	EPO 0273085	7/6/88	Europe			
	B3	WO 93/18790	9/30/93	PCT			
	B4	WO 94/17178	8/4/94	PCT			
	B5	WO 95/10601	4/20/95	PCT			
	B6	WO 95/19427	7/20/95	PCT			
	B7	WO 96/32116	10/17/96	PCT			
	B8	WO 98/22588	5/28/98	PCT			
	B9	WO 98/35554	8/20/98	PCT			
	B10	WO 99/12568	3/18/99	PCT			
	B11	WO 99/41416	8/19/99	PCT			
	B12	WO 00/34444	06/15/00	PCT			

25081695.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications of Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
INRP:067USD1/SLHSerial No.
09/941,296Applicant
Zheng Wu
Shuyuan ZhangFiling Date:
August 28, 2001Group:
1645U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Arap <i>et al.</i> , "Replacement of the <i>p16/CDKN2</i> gene suppresses human glioma cell growth," <i>Cancer Res.</i> , 55:1351-1354, 1995.
	C2	Caldas <i>et al.</i> , "Frequent somatic mutations and homozygous deletions of the <i>p16 (MTS1)</i> gene in pancreatic adenocarcinoma," <i>Nat. Genet.</i> , 8:27-32, 1994.
	C3	Carver <i>et al.</i> , "Transgenic livestock as bioreactors: stable expression of human alpha-1-antitrypsin by a flock of sheep," <i>Biotechnology NY</i> , 11:1263-1270, 1993.
	C4	Cheng <i>et al.</i> , " <i>p16</i> alterations and deletion mapping of 9p21-p22 in malignant mesothelioma," <i>Cancer Res.</i> , 54:5547-5551, 1994.
	C5	Cheung <i>et al.</i> , "Structure and function of C-CAM1," <i>J. Biol. Chem.</i> , 268:24303-24310, 1993.
	C6	Corveleyn and Remon, "Maltodextrins as lyoprotectants in the lyophilization of a model protein, LDH," <i>Pharm. Res.</i> , 13:146-150, 1996.
	C7	Croyle <i>et al.</i> , "Factors that influence stability of recombinant adenoviral preparations for human gene therapy," <i>Pharm. Dev. Technol.</i> , 3(3):373-383, 1998.
	C8	Ferkol <i>et al.</i> , "Regulation of the phosphoenolpyruvate carboxykinase/human factor IX gene introduced into the livers of adult rats by receptor-mediated gene transfer," <i>FASEB J.</i> , 7:1081-1091, 1993.
	C9	Fried and Bromberg, "Factors that affect the stability of protein-DNA complexes during gel electrophoresis," <i>Electrophoresis</i> , 18:6-11, 1997.
	C10	Hall <i>et al.</i> , "Stabilizing effect of sucrose against irreversible denaturation of rabbit muscle lactate dehydrogenase," <i>Biophys. Chem.</i> , 57:47-54, 1995.
	C11	Herman <i>et al.</i> , "The effect of bulking agent on the solid-state stability of freeze-dried methylprednisolone sodium succinate," <i>Pharm. Res.</i> , 11:1467-1473, 1994.
	C12	Hollestein <i>et al.</i> , "p53 mutations in human cancers," <i>Science</i> , 253:49-53 1991.
	C13	Hussussian <i>et al.</i> , "Germline p16 mutations in familial melanoma," <i>Nature Genetics</i> , 15-21, 1994.
	C14	Kamb <i>et al.</i> , "A cell cycle regulator potentially involved in genesis of many tumor types," <i>Science</i> , 267:436-440, 1994.
	C15	Kato <i>et al.</i> , "Expression of Hepatitis B virus surface antigen in adult rat liver," <i>J. Biol. Chem.</i> , 266:3361-3364, 1991.

25081695.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FEB 04 2002

RECEIVED

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

Form PTO-1449 (modified)

Atty. Docket No.
INRP:067USD1/SLHSerial No.
09/941,296

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Zheng Wu
Shuyuan ZhangFiling Date:
August 28, 2001Group:
1645U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C16	Kotani <i>et al.</i> , "Improved methods of retroviral vector transduction and production for gene therapy," <i>Human Gene Therapy</i> , 5:19-28, 1994.
	C17	Lu <i>et al.</i> , "Coat protein interactions involved in tobacco mosaic tobamovirus cross-protection," <i>Virology</i> , 248:188-198, 1998.
	C18	Lueckel <i>et al.</i> , "Formulations of sugars with amino acids or mannitol--influence of concentration ratio on the properties of the freeze-concentrate and the lyophilizate," <i>Pharm. Dev. Technol.</i> , 3:326-336, 1998.
	C19	Mori <i>et al.</i> , "Frequent somatic mutation of the <i>MTS1/CDK4I</i> (Multiple Tumor suppressor/Cyclin dependent Kinase 4 Inhibitor) gene in esophageal squamous cell carcinoma," <i>Cancer Res.</i> , 54:3396-3397, 1994.
	C20	Nobori <i>et al.</i> , "Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers," <i>Nature</i> , 368:753-756, 1995.
	C21	Perales <i>et al.</i> , "Gene transfer <i>in vivo</i> : sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake," <i>Proc. Natl. Acad. Sci. USA</i> , 91:4086-4090, 1994.
	C22	Racher <i>et al.</i> , "Culture of 293 cells in different culture systems: cell growth and recombinant adenovirus production," <i>Biotechnology Techniques</i> , 9:169-174, 1995.
	C23	Sagrera <i>et al.</i> , "Study of the influence of salt concentration on Newcastle disease virus matrix protein aggregation," <i>Biochem. Mol. Biol. Int.</i> , 46:429-435, 1998.
	C24	Serrano <i>et al.</i> , "Inhibition of ras-induced proliferation and cellular transformation by p16 ^{INK4} ," <i>Science</i> , 267:249-252, 1995.
	C25	Vanlandschoot <i>et al.</i> , "pH-dependent aggregation and secretion of soluble monomeric influenza hemagglutinin," <i>Arch. Virol.</i> , 143:227-239, 1998.
	C26	Vossen and Fried, "Sequestration stabilizes lac repressor-DNA complexes during gel electrophoresis," <i>Anal. Biochem.</i> , 245:85-92, 1997.
	C27	Weinberg, "Tumor suppressor genes," <i>Science</i> , 254:1138-1146, 1991.
	C28	Wu and Wu, "Liver-directed gene," <i>Adv. Drug Delivery Rev.</i> , 12:159-167, 1993.
	C29	Co-pending patent application U. S. Serial No: 08/975,519

25081695.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.